MedTrace Logo

A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B

NCT03625102 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-09-13

No results posted yet for this study

Summary

Hepatitis B virus infection is a worldwide disease and is still the most common cause of hepatocellular carcinoma (HCC).Existing treatments for hepatitis B infection have various side-effects including renal toxicity and drug resistance or failure.

Conditions

  • HBV

Interventions

DRUG

Antroquinonol

Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.

OTHER

placebo

The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects

Sponsors & Collaborators

  • Golden Biotechnology Corporation

    lead INDUSTRY

Principal Investigators

  • Ching-Pin Lin, MD · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2023-06-16
Completion
2023-06-16

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03625102 on ClinicalTrials.gov